Healthcare Industry News: Transdermal
News Release - February 3, 2010
Noven Appoints Patrick Gallagher as Vice PresidentMIAMI--(HSMN NewsFeed)--Noven Pharmaceuticals, Inc. today announced the appointment of Patrick Gallagher as the companyís new Vice President of Business Development. In this role, Gallagher will be responsible for all business development activities at Noven, including the in-licensing and out-licensing of new products and technologies, as well as the management and advancement of Novenís relationships with product development and commercialization partners. He will report to Jeff T. Mihm, Novenís Vice President, Chief Administrative Officer & General Counsel.
Gallagher has over 25 years' experience in the pharmaceutical, biotechnology and drug delivery industries. Prior to joining Noven, Gallagher served as Senior Vice President, Business Development, Marketing & Sales at Acusphere. Previously, he served as Vice President, Corporate Business Development at Mylan Laboratories. Earlier, he held senior director positions at Bristol-Myers Squibb and Johnson & Johnson. As a corporate development and strategic planning consultant, Gallagher has also helped pharmaceutical, biotech and medical device industry clients develop and successfully execute critical business initiatives.
Regarding Gallagherís appointment, Jeffrey Eisenberg, Novenís President and Chief Executive Officer, said: ďWeíre very pleased to welcome Patrick to the company. He joins Noven with substantial pharmaceutical industry experience developed at both large and small organizations, and Iím confident that he will help us meaningfully advance our growth initiatives through effective business development and alliance management activities.Ē
Noven Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products. Novenís business and operations are focused in three principal areas Ė Transdermal drug delivery, the Novogyne joint venture, and Noven Therapeutics, Novenís specialty pharmaceutical unit. Noven serves as the U.S. growth platform for Hisamitsu Pharmaceutical Co., Inc., which acquired Noven in August 2009. For more information about Noven, visit www.noven.com.
Source: Noven Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.